| MONOPAR THERAPEUTICS |
| USA |
| Gesundheit |
| US61023L2079 / A40JML |
| 1IY0 (Frankfurt) / MNPR (NASDAQ) |
| FRA:1IY0, ETR:1IY0, 1IY0:GR, NASDAQ:MNPR |
| - |
| https://www.monopartx.com.. |
|
Monopar Therapeutics Inc., a clinical-stage biopha..
>Volltext.. |
| 503 Mio. EUR |
| 457.98 Mio. EUR |
| - |
| -16.52 Mio. EUR |
| -14.96 Mio. EUR |
| -2.88 EUR |
| 0.1 Mio. EUR |
| 34.15 Mio. EUR |
| -8.48 Mio. EUR |
| 33.63 |
| - |
| -120.91% |
| - |
| - |
| - |
| - |
| MONOPAR |
| 09.11.25 |
|
||||
|
||||
|
||||
|
||||
|
||||
|